Category Archives: Inside BIO Industry Analysis

A Bright Future for Orphan Disease Indications

Chart

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals).   Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , ,

The IPO Road Less Traveled: Form 10

When investors talk about alternate exits for private companies beyond the traditional IPO they are usually referring to reverse mergers, if not outright acquisitions. However, another route is gaining some traction with sophisticated biotech investors – the so-called Form-10 pathway. Although it can be used in combination with reverse mergers, recent SEC rules applied to reverse mergers have shifted interest towards a more direct Form-10 approach to public markets. At last week’s BIO CEO & Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Ring

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears. At BIO’s recent CEO & Investor Conference, a panel of industry veterans gathered to discuss best practices in drug development partnering. Moderated by Jeff Stewart, Senior Engagement Manager with Campbell Alliance, the panel “Putting a Ring on it: When Drug Development Partnerships Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biobuck M&A in Full Gear

Graph

The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011.  What was not down however was the earnout structures embedded in these deals. More and more M&A transactions are looking like partnering deals structured with CVRs accounting for the bolus of the reported purchase price. Here is a look at therapeutic-focused acquisitions (valued at >$10M) over the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

A Big Year for Novel Drugs Approvals

What was your top Biopharma highlight for 2012? If it wasn’t the stellar move in the AMEX Biotech Index (up 42%), or the reauthorization of PDUFA, then perhaps it was the decade high for innovative drugs approvals. We would need to go back to the 1990s to find a year with as many FDA approvals for novel drugs as we had in 2012. Adding to the positive trend in numbers, up 29% from the robust Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post